1-6 of 6
John Pesko
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

ReVenG: A Phase 2 Study of Venetoclax Plus Obinutuzumab Retreatment in Patients with Relapsed Chronic Lymphocytic Leukemia

Matthew S. Davids, Kirsten Fischer, Sandra Robrecht, Can Zhang, Inhye E. Ahn, Michele Porro Lurà, Wendy Sinai, Brenda Chyla, Kavita Sail, John Pesko, Madhavi Pai, Viktor Komlosi, Michael Hallek, Jennifer R. Brown, Othman Al-Sawaf
Journal: Blood
Blood (2021) 138 (Supplement 1): 2634.
https://doi.org/10.1182/blood-2021-153033
Published: 2021
Journal Articles

Debulking before Initiation of Venetoclax Therapy in Untreated Patients with Chronic Lymphocytic Leukemia: Results from a Phase 3b Study

Ian W. Flinn, David Andorsky, Jason Melear, Sudhir Manda, Bertrand Anz, III, Kathryn Kolibaba, Habte Yimer, John M. Burke, Suzanne Fanning, Jay Courtright, Miguel Islas-Ohlmayer, Suman Kambhampati, Tamas Vizkelety, John Pesko, Brenda Chyla, Dingfeng Jiang, Jeff P. Sharman
Journal: Blood
Blood (2021) 138 (Supplement 1): 3725.
https://doi.org/10.1182/blood-2021-147258
Published: 2021
Journal Articles

Efficacy of venetoclax plus rituximab for relapsed CLL: 5-year follow-up of continuous or limited- duration therapy

Clinical Trials & Observations
Shuo Ma, John F. Seymour, Danielle M. Brander, Thomas J. Kipps, Michael Y. Choi, Mary Ann Anderson, Kathryn Humphrey, Abdullah Al Masud, John Pesko, Ruby Nandam, Ahmed Hamed Salem, Brenda Chyla, Jennifer Arzt, Amanda Jacobson, Su Young Kim, Andrew W. Roberts
Journal: Blood
Blood (2021) 138 (10): 836–846.
https://doi.org/10.1182/blood.2020009578
Published: 2021
Includes: Supplemental data
Journal Articles

Phase I/II Study Evaluating the Safety and Efficacy of Venetoclax in Combination with Dexamethasone As Targeted Therapy for Patients with t(11;14) Relapsed/Refractory Multiple Myeloma

Jonathan L. Kaufman, MD, Cristina Gasparetto, MD, Fredrik H. Schjesvold, MD PhD, Philippe Moreau, MD, Cyrille Touzeau, MD, Thierry Facon, MD, Lawrence H. Boise, PhD, Stefanie Alzate, MSc, Tammy Macartney, John Pesko, PhD, Ahmed Hamed Salem, PhD FCP, Jeremy A. Ross, PhD, Wan-Jen Hong, MD, Paulo C. Maciag, MD PhD, James M. Pauff, MD PhD, Shaji K. Kumar, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 926.
https://doi.org/10.1182/blood-2019-125871
Published: 2019
Journal Articles

First Analysis from a Phase 1/2 Study of Venetoclax in Combination with Daratumumab and Dexamethasone, +/- Bortezomib, in Patients with Relapsed/Refractory Multiple Myeloma

Nizar Bahlis, MD, Rachid Baz, MD, Simon Harrison, MBBS, MRCP, FRCPath, FRACP, PhD, Hang Quach, MBBS, FRACP, FRCPA, MD, Shir-Jing Ho, MBBS, FRACP, FRCPA, MClinTrial Res, Annette Juul Vangsted, MD PhD, Philippe Moreau, MD, Simon Gibbs, FRACP, FRCPA, MBBS, Ahmed Hamed Salem, PhD FCP, Jeremy A. Ross, PhD, John Pesko, PhD, Sally Westrup, Jenny Vue, Paulo C. Maciag, MD PhD, Orlando F. Bueno, MD PhD, Jonathan L. Kaufman, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 925.
https://doi.org/10.1182/blood-2019-124407
Published: 2019
Journal Articles

Phase 2 Study of Venetoclax Plus Carfilzomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma

Luciano J Costa, MD PhD, Edward A. Stadtmauer, MD FACP, Gareth Morgan, MD, Gregory Monohan, MD, Tibor Kovacsovics, MD, Nicholas Burwick, MD, Andrzej Jakubowiak, MD PhD, Jonathan L Kaufman, MD, Mehrdad Mobasher, MD MPH, Kevin J. Freise, PhD, Jeremy A. Ross, PhD, John Pesko, PhD, Wijith Munasinghe, PhD, Saketh Gudipati, MD, Sarah Mudd, PhD, Orlando Bueno, MD PhD, Shaji K. Kumar, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 303.
https://doi.org/10.1182/blood-2018-99-117026
Published: 2018